Influenza Virus Replication via Growth-Enhancing Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines face challenges in achieving high titers in cell culture and embryonated chicken eggs, leading to inefficient and costly vaccine production, particularly due to the high variability of the HA protein and the need for robust replication of influenza viruses.
Innovation Solution
Identification and combination of growth-enhancing mutations in specific residues of influenza virus polypeptides, such as PA, PB1, PB2, NP, and NS proteins, to enhance viral replication in cell culture and eggs, resulting in higher titers and more efficient vaccine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional influenza vaccine production methods are used, then vaccine production can proceed with standard protocols, but viral titers remain low and production efficiency is poor
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations in the HA protein (such as E193D, E194D, E195D substitutions) and internal protein mutations (PB2, PB1, PA, NP, M, NS1) to optimize viral replication parameters. These parameter changes in protein structure and function directly increase viral titers from conventional levels to enhanced levels, resolving the contradiction between production efficiency and viral titer quantity.
2Adaptability or versatility
If the HA protein is highly variable to accommodate antigenic diversity, then vaccine coverage can be improved, but replication stability and consistency deteriorate
Solution Approach 1:
The patent segments the influenza virus into distinct functional modules: the HA protein maintains antigenic variability for adaptability, while separate internal proteins (PB2, PB1, PA, NP, M, NS1) with specific mutations provide replication stability. This segmentation allows the virus to simultaneously achieve high adaptability through HA variation and stable replication through conserved internal protein functions, resolving the contradiction between these two opposing requirements.
Solution Approach 2:
The patent applies local quality by introducing specific mutations at particular positions in each protein (e.g., E193D in HA, M202 in PB2, Q247 in PB1, R74 in NP, V97/Y100 in M1, K55 in NS1). Each local mutation is optimized for its specific function: HA mutations for antigenic properties, internal protein mutations for replication efficiency. This localized optimization allows simultaneous achievement of adaptability and stability.
3Ease of manufacture
If vaccine production uses standard influenza virus strains, then production processes remain simple, but costs increase due to low yield
Solution Approach 1:
The patent changes the genetic parameters of the vaccine virus by introducing specific mutations in the backbone strain (A/Puerto Rico/8/34 H1N1). These parameter changes in amino acid sequences enhance replication efficiency and viral yield without fundamentally altering the production process. The mutated virus can be produced using existing manufacturing workflows, maintaining ease of manufacture while dramatically increasing vaccine yield and reducing costs.
Data Source
AI summary
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.